Eli Lilly Launches Reyvow (lasmiditan) C-V for the Treatment of Migraine in the US

Shots:

• Eli Lilly launches Reyvow C-V 50/100/200mg, indicated for the acute treatment of migraine with/without aura & will be available in US pharmacies in the next few days
• The efficacy of the therapy is evaluated in SAMURAI and SPARTAN studies assessing Reyvow vs PBO in 4439 patients with migraine, results demonstrated that patients achieved fast and complete elimination of migraine pain @2hrs. (28-39% vs 15% & 21%), patients achieved MBS @2hrs. (41-49% vs 30% & 33%)
• Reyvow is a 5-HT1F receptor agonist, the first and only FDA-approved ditan, designed to act both centrally and peripherally and has received approval in Oct’2019

Click here ­to­ read full press release/ article | Ref: Eli Lilly | Image: StraitTimes